Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Plans To Expand Coverage For Home Anticoagulation Monitoring

This article was originally published in The Gray Sheet

Executive Summary

CMS is proposing to expand coverage for home anticoagulation management, which could be a boon to diagnostics products made by Thoratec, Inverness Medical Innovations and Roche

You may also be interested in...



Home anti-coagulation monitoring

Medicare coverage is expanded for home blood testing of prothrombin time to include beneficiaries who are using the blood thinner warfarin for chronic atrial fibrillation or venous thromboembolism in a March 19 final coverage determination. Home International Normalized Ratio (INR) prothrombin time monitoring is already covered for patients with mechanical heart valves. The new policy should be a boon for three device firms that market INR assays for home use - Thoratec/International Technidyne (ProTime Microcoagulation System), Inverness/HemoSense (INRatio) and Roche Diagnostics (CaguChek XS and Coaguchek PST) ("1The Gray Sheet" Jan. 7, 2008, p. 16)

Home anti-coagulation monitoring

Medicare coverage is expanded for home blood testing of prothrombin time to include beneficiaries who are using the blood thinner warfarin for chronic atrial fibrillation or venous thromboembolism in a March 19 final coverage determination. Home International Normalized Ratio (INR) prothrombin time monitoring is already covered for patients with mechanical heart valves. The new policy should be a boon for three device firms that market INR assays for home use - Thoratec/International Technidyne (ProTime Microcoagulation System), Inverness/HemoSense (INRatio) and Roche Diagnostics (CaguChek XS and Coaguchek PST) ("1The Gray Sheet" Jan. 7, 2008, p. 16)

Inverness Stays Homeward Bound With $1.18 Billion Matria Buy

Inverness Medical Innovations will continue to expand beyond its rapid point-of-care diagnostics business and into the health management services sector through its $1.18 billion acquisition of Matria Healthcare, announced Jan. 28

Related Content

UsernamePublicRestriction

Register

MT025620

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel